Cargando…
Impact of 5-HT(3) receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study
BACKGROUND: 1(st) generation 5-hydroxytryptamine receptor antagonists (5-HT(3) RAs), and palonosetron, a 2(nd) generation 5-HT(3) RA, are indicated for the prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) associated with moderately (MEC) and highly emetogenic CT agents (HEC). This...
Autores principales: | Lin, Swu-Jane, Hatoum, Hind T, Buchner, Deborah, Cox, David, Balu, Sanjeev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437203/ https://www.ncbi.nlm.nih.gov/pubmed/22823909 http://dx.doi.org/10.1186/1472-6963-12-215 |
Ejemplares similares
-
Comparative clinical effectiveness of various 5-HT(3) RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice
por: Hatoum, Hind T., et al.
Publicado: (2011) -
Role of dexamethasone dosage in combination with 5-HT(3) antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting
por: Münstedt, K, et al.
Publicado: (1999) -
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018) -
Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015) -
Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting
por: Ruhlmann, Christina, et al.
Publicado: (2009)